NCT05644717View on ClinicalTrials.gov

Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD

PHASE4RecruitingINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

November 1, 2025

Study Completion Date

December 1, 2025

Conditions
Liver FatLiver FibrosisGlycemic ControlBody Weight ChangesWaist CircumferenceTolerance
Interventions
DRUG

Ertugliflozin 5 mg, 15mg

Ertugliflozin 5/15mg once daily in addition to standard of care

Trial Locations (1)

Unknown

RECRUITING

North west general hospital, Peshawar

Sponsors

Lead Sponsor

Getz Pharma
All Listed Sponsors
lead

Getz Pharma

INDUSTRY

NCT05644717 - Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD | Biotech Hunter | Biotech Hunter